SOPHiA GENETICS (NASDAQ:SOPH) Director Kathy Hibbs Sells 6,250 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Director Kathy Hibbs sold 6,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $8.68, for a total value of $54,250.00. Following the transaction, the director directly owned 103,242 shares of the company’s stock, valued at approximately $896,140.56. The trade was a 5.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock opened at $8.53 on Thursday. The stock has a market capitalization of $715.58 million, a P/E ratio of -7.42 and a beta of 0.96. The company’s fifty day moving average price is $6.39 and its 200 day moving average price is $5.40. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a 1 year low of $3.10 and a 1 year high of $8.85.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. As a group, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

SOPH has been the topic of a number of research reports. HC Wainwright raised their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, BTIG Research upped their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, SOPHiA GENETICS has an average rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The stock reached a new 12-month high, signaling strong recent momentum and investor interest. SOPHiA GENETICS Sets New 12-Month High
• Neutral Sentiment: Reported short interest was zero shares as of August 25, implying no measurable short-selling pressure. The data also showed no meaningful change from the prior period, limiting its usefulness as a trading signal.
• Negative Sentiment: CTO Abhimanyu Verma sold 5,000 shares for approximately $44,000 on August 24, reducing his position by 2.82%. Because the sale followed a pre-arranged Rule 10b5-1 plan, it may not reflect a current change in the executive’s outlook. SEC Form 4 filing
• Negative Sentiment: Director Kathy L. Hibbs sold 6,250 shares worth about $54,250 on August 25, decreasing her holdings by 5.71%. The sale adds to near-term insider-selling concerns but was also executed under a 10b5-1 plan. SEC Form 4 filing
• Negative Sentiment: Insider Philippe Menu sold 5,000 shares for approximately $43,400 on August 25, reducing his position by 2.29%. The transaction was pre-planned, which moderates—but does not eliminate—the potential negative signal from multiple insider sales. SEC Form 4 filing

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SOPH. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS in the fourth quarter valued at $49,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS during the third quarter valued at about $49,000. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd acquired a new position in shares of SOPHiA GENETICS in the 4th quarter worth approximately $55,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.